SL-1002 is under clinical development by Saol Therapeutics and currently in Phase II for Lower Limb Muscle Spasticity. According to GlobalData, Phase II drugs for Lower Limb Muscle Spasticity does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SL-1002 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SL-1002 overview

SL-1002 is under development for the treatment of mild to severe lower and upper limb spasticity. It is administered through parenteral route.

Saol Therapeutics overview

Saol Therapeutics (Saol) is a pharmaceutical company develops and manufactures therapeutic products for neuroscience and other rare diseases. The company offer pipeline products such as SL – 1002, SL – 1009 and its targeted areas of research include pain related to Osteoarthritis (OA) of the Knee, Spasticity, Pyruvate Dehydrogenase Complex Deficiency (PDCD). It is are also focused on the acquisition of approved prescription products and clinical development stage compounds. Soal partner with pharmaceutical and biotechnology companies and academia. The company has operations in Dublin, Ireland. Saol is headquartered in Roswell, Georgia, the US.

For a complete picture of SL-1002’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.